Why FDA places IND applications on clinical hold

Why FDA Places IND Applications on Clinical Hold: Common CMC Mistakes and How to Avoid Them

Biotech teams pour energy into pharmacology, toxicology, and clinical rationale—then treat Chemistry, Manufacturing, and Controls (CMC) as a last-minute documentation task. That’s a strategic error. FDA can and does hold INDs for CMC deficiencies even when the biology is compelling, because the agency’s first question is not “Does it work?” but “Do you know what you’re giving humans, and can you make it consistently and safely?”^[1][2][3]

CMC is not Module 3 paperwork. It is the scientific backbone that proves identity, strength, quality, purity, and performance of the clinical material—and it starts at process design, not at submission.^[1][4][5]

• The Misconception About IND Success

Typical answers to “What drives IND success?”:

• Strong pharmacology
• Robust toxicology
• Innovative MoA

All necessary, none sufficient. Regulators ask first:

“How do you know the material administered to humans is consistently manufactured, adequately characterized, and safe for clinical investigation?”

That is a CMC question. An IND is permission to expose humans to your product only if you can show reasonable assurance that the material is controlled and representative of what you intend to develop.^[1][6][7]

• Common FDA CMC Deficiencies in IND Applications
• Scientific optimism: “We’ll fix manufacturing after we see clinical signal.”
• Resource constraints: CMC competes with discovery, toxicology, and clinical ops for limited budgets.
• Phase-appropriate confusion: Some under-build Phase 1 CMC; others over-engineer and burn cash without regulatory payoff.^[2][6]
• Fragmented ownership: Process, analytics, QA, regulatory, and CDMOs work in silos, producing a disjointed Module 3.

Result: a scramble to assemble Module 3 from documents never designed for regulatory use.

• What CMC Actually Does

CMC provides the evidence that the investigational product is suitable for human administration. A strong package answers:

• What is the drug substance (and drug product)?
• How is it made, and how consistent is the process?
• What impurities/variants exist, and how are they controlled?
• How is quality measured and assured (specifications, methods, controls)?
• How stable is it over the intended clinical use period?
• Will every subject receive comparable material, even if the process evolves?^[1][5][8]

FDA’s stance is explicit: CMC information must be phase-appropriate but always sufficient to protect trial participants.^[1][2][7]

• CMC ≠ Module 3

Module 3 is the output of earlier decisions:

If these are not planned with submission in mind, Module 3 becomes damage control, not a coherent quality story.^[4][9][10]

• The Real Cost of Weak CMC

Typical consequences:

• FDA information requests and clinical holds
• Delayed first-patient-in and site activation
• Comparability exercises after process changes
• Repeated method redevelopment and unplanned stability work
• Higher burn, eroded investor confidence, and stalled partnerships^{[3][4][6][10]}

For small biotech, even a 60–90 day CMC delay can jeopardize financing windows.

Our Insights

The best IND programs don’t produce better documents—they build better quality knowledge. Sponsors who treat CMC as a lifecycle capability:

• Make faster, more defensible regulatory decisions
• Respond crisply to FDA questions with data, not narratives
• Create reusable, structured content that scales from IND → NDA/BLA

This is exactly where deep regulatory/CMC expertise adds value: translating FDA’s risk-based, phase-appropriate expectations into a pragmatic, audit-ready development plan.^[1][2][8]

Planning an IND submission?

Our regulatory experts perform a comprehensive CMC readiness assessment to identify gaps before FDA does. We turn CMC from a hurdle into a development accelerator:

• Phase-appropriate CMC strategy aligned to your modality (small molecule, biologic, CGT)^[1][5][8]
• IND readiness and gap assessments focused on FDA’s common CMC deficiency patterns^[3][4][10]
• Drug substance/product data reviews and control strategy design
• Module 3 authoring with QC that anticipates reviewer questions
• Analytical and stability strategies that cover the clinical use period without over-engineering^[1][6]
• Pre-IND interaction prep and mock Health Authority reviews
• Structured, digital CMC knowledge management to support lifecycle submissions

Goal: a CMC package that clears the IND, de-risks development, and lays a clean path to later-stage filings.

Key Takeaways

• CMC is underestimated because it’s seen as documentation, not science. In reality, it is how regulators judge whether your product is fit for human use.^[1][7]
• Early investment in process understanding, analytics, stability, and control strategy reduces regulatory risk and accelerates timelines.^[2][3][4]
• As FDA pushes phase-appropriate, knowledge-driven submissions, sponsors with strong CMC governance will move faster and more predictably through the IND lifecycle.^[1][2][8]

Sources

1. 1IND Applications for Clinical Investigations: Chemistry, Manufacturing
2. 2FDA Actions to Accelerate and Modernize Early and Late- ...
3. 3De-Risking IND Submissions to Accelerate FDA Clearance
4. 4Quality Gaps Delaying Drug Development Milestones
5. 5CMC for a Cell or Gene Therapy IND
6. 6IND Application: Step-by-Step FDA Filing Guide May 2026
7. 7What and How Much to Write in the Phase 1 CMC Section
8. 8FDA GUIDANCE: Chemistry, Manufacturing, and Control ...
9. 9Building the Quality (CMC) Section (Mod 3) for an IND - LinkedIn
10. 10Why CMC Gaps Delay Regulatory Submissions | TDP
11. 11Cellular & Gene Therapy Guidances
12. 12Investigational New Drug (IND) Application
13. 13Phase 1 IND Guidance Documents - FDA
14. 14Chemistry Manufacturing and Controls (CMC) Guidances ...
15. 15U.S. Food and Drug Administration - CITC 2024 – D2S01 ...